Stockreport

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Scholar Rock Holding Corporation (SRRK)

More Company Research Source: Business Wire

Last scholar rock holding corporation earnings: 11/12 07:30 am Check Earnings Report

PDF Apitegromab remains on track to be the first and only muscle-targeted treatment for people living with Spinal Muscular AtrophyFDA to review BLA application under priorit [Read more]

EVENT DAY Stock performance from the time of news release until the following 4pm ET market close	LAST PRICE AT NEWS EVENT {{SecondSection.LastPriceAtNewsEvent}}	SINCE EVENT Multi-day stock performance from the time of the news release
{{FirstSection.LastPrice}}	LAST PRICE	{{SecondSection.LastPrice}}
{{FirstSection.VWapStr_AMP}} {{FirstSection.VwapEventTime}}	VWAP	{{SecondSection.VWapStr_AMP}} {{SecondSection.VwapEventTime}}
{{FirstSection.MaxUp}} High: {{FirstSection.EodHigh}}	MAX UP	{{SecondSection.MaxUp}} High: {{SecondSection.EodHigh}}
{{FirstSection.MaxDown}} Low: {{FirstSection.EodLow}}	MAX DOWN	{{SecondSection.MaxDown}} Low: {{SecondSection.EodLow}}
{{FirstSection.TodaysRangeStr_AMP}} {{FirstSection.RangEvg}}	POST NEWS RANGE	{{SecondSection.TodaysRangeStr_AMP}} {{SecondSection.RangEvg}}
{{FirstSection.PriceChange}} {{FirstSection.PriceChangeTriangle_AMP}}	PRICE CHANGE	{{SecondSection.PriceChange}} {{SecondSection.PriceChangeTriangle_AMP}}
{{FirstSection.PriceChangePercent}}	PRICE CHANGE PERCENTAGE	{{SecondSection.PriceChangePercent}}
{{FirstSection.Spx500}}	S&P 500 (SPX)	{{SecondSection.Spx500}}
{{FirstSection.VolumeImpactStr_AMP}}	VOLUME RATIO	{{SecondSection.VolumeImpactStr_AMP}}
{{FirstSection.Volume}}	VOLUME (SHARES)	{{SecondSection.Volume}}
{{FirstSection.TicksString}}	TICKS	{{SecondSection.TicksString}}
{{FirstSection.AvgTransactionSizeStr_AMP}}	AVG SHARES PER TRADE	{{SecondSection.AvgTransactionSizeStr_AMP}}

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

{{GreenBoxData.Blurb}}

Opt in for alerts from News Quantifed